Duchenne muscular dystrophy (DMD) is a progressive, life-limiting muscle-wasting disease. Although no curative treatment is yet available, comprehensive multidisciplinary care has increased life expectancy significantly in recent decades. An international consensus care publication in 2010 outlined best-practice care, which includes corticosteroid treatment, respiratory, cardiac, orthopedic and rehabilitative interventions to address disease manifestations. While disease specialists are largely aware of these care standards, local physicians responsible for the day-to-day care of patients and families may be less familiar. To facilitate optimal care, a one-page document has been generated from published care recommendations, summarizing the key elements of comprehensive care for people living with DMD (“Imperatives for Duchenne muscular dystrophy). This document was developed through an international collaboration between Parent Project Muscular Dystrophy (PPMD), United Parent Projects Muscular Dystrophy (UPPMD) and TREAT-NMD.
Funding StatementThe authors received no specific funding for this work.
The muscular dystrophies (MD) are a group of genetically heterogeneous muscle diseases marked by progressive wasting and weakness of the skeletal and cardiac muscles1. Duchenne muscular dystrophy (DMD) is the most common and most severe form. It is an X-linked disorder affecting 1 in 5000 live male births2,3. DMD is caused by mutations in the DMD gene, which encodes the muscle fiber membrane protein dystrophin. Deficiency or complete absence of dystrophin makes muscle fibers sensitive to damage upon contraction, leading to plasma membrane leakage and muscle fiber degeneration, which eventually leads to progressive muscle degeneration and loss of ambulation4.
The average age at diagnosis of Duchenne is approximately five years, but delays in motor milestones (such as sitting, standing independently, climbing, and walking), and cognitive development (such as expressive language, receptive language, visual-spatial skills, attention and memory) occur much earlier5,6. Untreated, children with DMD lose their ability to walk independently and become reliant on wheelchairs for mobility between the ages of 7 and 13. Most individuals with Duchenne experience serious respiratory, orthopedic, and cardiac complications. By the age of 18, the majority of patients require ventilation support at night7,8. The average life expectancy is approximately 30 years7, with respiratory complications and cardiomyopathy being common causes of death.
Standard management of Duchenne requires multidisciplinary care that includes the use of corticosteroids as well as respiratory, cardiac, orthopedic, and rehabilitative interventions addressing both the primary and secondary manifestations of the disease5,7. Corticosteroids slow the progression of muscle weakness and delay some of the complications of the disease, but they do not treat or correct the underlying causes of Duchenne5. The use of corticosteroids comes with a high frequency of significant side effects, including behavior change, weight gain, osteoporosis, slowed growth and delayed puberty, and others, which should be monitored by the treating physician.
In an effort to optimize care for DMD patients, international care guidelines for DMD were published in Lancet Neurology in 2009, the generation of which involved more than 80 DMD experts and patient organization representatives5,7. These guidelines highlight the need for a multidisciplinary approach to provide comprehensive care for DMD patients, addressing both the primary and secondary manifestations of the disease and include baseline parameters for key areas, including neurology/steroids, cardiology, pulmonary, physical therapy/physical medicine and rehabilitation, orthopedics, surgical considerations, and psychosocial care. Patient advocacy groups9,10 worked with the TREAT-NMD alliance11 to create a family friendly lay version of the guidelines, to help empower parents and patients to advocate for comprehensive care12. This family-friendly document, while abbreviated, is still over 30 pages long.
Employee of LUMC which holds patents on exon skipping, and entitled to royalties as the co-inventor. Ad-Hoc consultant for PTC Global GuidePoint and GLC consultancy which provides remuneration to my institute.
Comprehensive multidisciplinary care provided by a care team familiar with DMD has been demonstrated to be the best model of care for people living with DMD7. However, some individuals live in areas where access to this model is not possible and there is increasing evidence that compliance to the published care standards is patchy at best13,14,15. Furthermore, many DMD patients will visit a team of specialists on a yearly basis and rely on local physicians for their basic care. Since these physicians are generally not DMD specialists, parents and patients need to become DMD experts in order to advocate for their disease specific needs16. To assist providers who may have little DMD expertise, in providing patients with comprehensive care, we have generated the “Imperatives for DMD” (Figure 1). This international effort, that involved both clinicians and patient organizations, has resulted in the generation of a one-page document listing the essential elements of comprehensive care for people living with DMD. The mnemonic, DUCHENNE MD, was chosen as an aide-mémoire to the key recommendations in each area of care.
The authors of the Imperatives for DUCHENNE MD, and professionals acknowledged for their participation in this effort, have expertise covering all of the subspecialty areas included in the international care guidelines, and many were involved in the creation of the original guidelines. Each area of the care guidelines was evaluated for consistency with current practices and care. Areas of care that have evolved since the 2009 publication were updated in the Imperatives (i.e., encouraging the use of corticosteroids early (by age 4 years old or as soon as possible after diagnosis if after age 4) and using caution with all anesthesia). Key points from each of the areas of care in the care guidelines were identified and consolidated to develop the single page “Imperatives for DUCHENNE MD.“ While the Imperatives for DUCHENNE MD is not expected to replace the published detailed care guidelines5,7, these simplified care recommendations may serve as an orientation to care for both medical providers not familiar with this population, as well as patients/families.
The imperatives include:
A high serum CK is indicative of muscle damage. It is good to bear in mind that skeletal muscle also contains transaminases. The combination of elevated CK and transaminases points to extensive skeletal muscle damage (such as occurs for DMD), rather than liver damage. As discussed above, most children with Duchenne demonstrate delayed motor and/or cognitive development. Therefore, if an elevated CK is found in conjunction with developmental delay and/or elevated transaminases, full genetic testing should be done. If the child is diagnosed with DMD, carrier testing for the mother should be discussed. Mothers who have children with Duchenne have a 66% chance of being diagnosed as a carrier17. Definitive testing will allow the couple to make informed decisions regarding future family planning.
2. Use Support
Comprehensive multidisciplinary care provided by a care team familiar with Duchenne has been demonstrated to be the best model of care for people living with Duchenne5,7. Parents faced with the diagnosis of Duchenne are understandably shocked, overwhelmed and grieving. Parents should be encouraged to seek support from other parents either through formally established programs or informally through responsible online resources18.
In the US, the first symptoms of Duchenne are usually noticed at 2.5 years of age; the average of diagnosis, however, is 4.9 years old19 while the median age diagnosis is 4 years old of patients in Europe20. Initiation of corticosteroids is recommended at least by ages 4 and 6 years, before motor skills begin to decline7,8. In light of these perceptions and recommendations, it was felt that initiating steroids early would increase their benefit (as soon as diagnosed if after age 4-6 years, and before motor skills begin to decline if diagnosed before ages 4-6 years). Discussing the risks and benefits of corticosteroid use by age 3 years (if diagnosed before age 3 years) would give parents and caregivers time to consider the pros and cons of using of this medication before the motor skills begin to decline.
Due to deterioration of cardiac muscles, those living with DMD are at a high risk of developing dilated cardiomyopathy and/or cardiac arrhythmia, which often present few clinical symptoms until well advanced7. Heightened vigilance of Duchenne providers, including EKG, imaging, and staged interventions when appropriate, is therefore warranted from diagnosis and performed at least annually after age 107. Female carriers of DMD are also at increased risk of developing cardiomyopathy21, and should be screened in early adulthood and followed with echocardiogram or cardiac MRI and EKG every five years22.
5. Every Visit:
Those with DMD are at risk of both over- and underweight at different stages of the disease, necessitating regular monitoring and dietary adjustments as appropriate7,23. Chronic steroid use can increase risk of younger patients becoming overweight, while older patients, especially those who develop dysphagia, may be at risk for aspiration and losing weight. GERD (gastro-esophogeal reflux) and constipation are the two most commonly reported gastrointestinal conditions reported by children with DMD, and should be treated if they occur7. Adequate Vitamin D and calcium intake are also important in maintaining bone health (see below).
6. Never forget Physical and Occupational therapy, physical medicine and rehabilitation
Regular stretching, and the use of appropriate splints where necessary, helps to prevent the development of contractures and maintain flexibility of joints in those with DMD5. Amongst younger children, stretching helps to preserve ambulation; once non-ambulant, stretching is important to help maintain useful upper body function (particularly the use of arms and hands) for as long as possible. Assistive devices such as resting orthoses can help to prevent upper and lower limb contractures, while wheelchairs (initially manual, to prevent overexertion, but later powered) help to maintain independence and societal participation.
7. Nor Bone density
Those on chronic steroid treatment are at risk of fractures. In DMD vertebral fractures are a particular risk, and can be minimized by monitoring and supplementation of vitamin D5. Bone density measurement is recommended, while bisphosphonates may also be appropriate. Scoliosis amongst those not treated with steroids is common in DMD and should be monitored carefully. Where necessary, spinal fixation might be required7.
8. Evaluate breathing
Respiratory decline progressing to failure is a significant complication of DMD. Preventing pulmonary complications with up to date immunizations, pneumonia and annual influenza vaccine is critical7. Pulmonary function should be assessed at least once while ambulatory and at least annually after loss of ambulation, with interventions staged appropriately24. Following the loss of ambulation, the onset of pulmonary dysfunction is slow and progressive requiring the use of assistive devices. These assist devices generally progress from cough assistance during respiratory illness, to assistance with daily cough, then nocturnal non-invasive ventilation (NIV) and, progressing to continuous NIV (if required). While NIV is generally preferred, in some cases, both patients and pulmonologists have preferred invasive ventilation. Effective airway clearance is essential for the prevention of atelectasis and pneumonia. A peak cough expiratory flow rate of 270 L/min has been designated as the level at which assistive airway clearance (cough assist) is necessary24. Sleep disordered breathing and alveolar hypoventilation are both associated with Duchenne and are often subtle and asymptomatic24. For this reason, polysomnography (or overnight pulse oxymetry, only if polysomnography is not available) and the use of BiPAP (bi-level positive airway pressure) is recommended if clinically indicated and/or when the FVC < 30%7.
9. Mental Health
Comprehensive medical care must also include support for the patient and family’s psychosocial wellbeing5. Those with DMD and their families face challenges shared by those living with other chronic, life-limiting conditions, which may include marginalization, social isolation, depression, anxiety, and others5. Patients with Duchenne have been found to be at increased risk for coexisting issues, such as learning difficulties, speech and language problems, and ADD/ADHD/OCD, which may compound these challenges. Psychosocial difficulties should be treated with the same interventions as used in the general population to maximize outcomes and enable full social participation. Improvements in medical care have created a new population of adults living with Duchenne. In light of this change, health, education and social services must be encouraged to provide lifelong support to those living with Duchenne25.
We recommended that patients and families keep copies of their medical information, and key information about DMD (in the form of an Alert Card or similar), with them at all times. As DMD is a rare condition, non-specialist medical personnel are often unfamiliar with best-practice care or absolute contraindications. Particularly during an emergency, having this information to hand can prevent inappropriate and potentially life-threatening treatment13.
There has been general concern in the Duchenne community regarding the use of volatile agents (inhaled agents used for general anesthesia) and the risk of rhabdomyolysis, however the use of these agents and the subsequent development of rhabdomyolysis and hyperkalemia unrelated to malignant hyperthermia remains controversial26. In addition, rhabdomyolysis has been reported with the use of non-triggering agents26,27,28. Therefore, the group has recommended that patients be monitored when any anesthesia is used. The use of succinylcholine (a depolarizing agent), however, remains an absolute contraindication in this population26,27.
Notably, most of these Imperatives are in agreement with the aforementioned care guidelines. There are, however, two imperatives that have been updated with regards to new evidence and current expert opinion: the use of corticosteroids and caution with anesthesia.
“Imperatives for Duchenne MD” is a very focused and brief snapshot of the essential components of comprehensive DMD care as described in the CDC care considerations. This information is meant for health care providers, but can also be used by patients and parent advocating for comprehensive care for themselves or their children. The document has so far been translated into 18 languages by patient organizations and professional volunteers around the world through the TREAT-NMD Alliance.
More detailed information for each area of care and the care required for each stage of Duchenne, as well as the complete publication of the care guidelines are available both online and in print5,7. These publications and the Family Friendly version of the care guidelines are available at the TREAT-NMD website as well.
Parent Project Muscular Dystrophy (PPMD)
Parent Project Muscular Dystrophy (PPMD, www.parentprojectmd.org)9 is the largest nonprofit organization in the United States focused entirely on Duchenne. Started in 1994 by Pat Furlong, PPMD takes a comprehensive approach in the fight against Duchenne—funding research, raising awareness, promoting advocacy, connecting the community, and broadening treatment options. PPMD’s care objectives are to identify gaps in care for people with Duchenne and work toward solutions, and to work with clinicians and other health care professionals across the globe to ensure all Duchenne patients have access to optimal care.
United Parents Project Muscular Dystrophy (UPPMD)
Duchenne Parent Organizations combine their strength through the worldwide network organization UPPMD (www.uppmd.org)10. UPPMD is dedicated to finding a cure and viable treatments for DMD, to promoting good standards of care and to informing parents around the globe. There is a compelling need to ensure that wherever they are in the world, the children suffering from this disease can benefit from a standard of care that is informed by the best practice of the best clinicians from all over the world.
The TREAT-NMD Alliance (www.treat-nmd.eu)11 is an international translational network dedicated to the neuromuscular field, which brings together researchers, clinicians, patient advocacy organizations. Initially funded as a “Network of Excellence” by the European Union’s 6th Framework Programme (FP6) (2007-2011), it has been maintained and broadened to become a global alliance. TREAT-NMD addresses bottlenecks in the translational process of therapy development for rare, inherited neuromuscular disorders. It provides and links infrastructure tools such as patient registries, biobanks, and standards of care. The global governance structure of TREAT-NMD reserves one third of the Executive Committee positions for patient representatives.
AcknowledgementsThe following people are acknowledged for their advice and helpful comments: James Dowling, Sick Kids, Toronto, Canada; Norbert Weidner, Cincinnati Children’s Hospital Medical Center, Cincinnati, OH, USA; Brenda Wong, Cincinnati Children’s Hospital Medical Center, Cincinnati, OH, USA; Linda Cripe, Nationwide Children’s Hospital, Columbus, OH, USA; Doug Biggar, Holland Bloorview Kids Rehab, Toronto, Canada, Garey Noritz, Nationwide Children’s Hospital, Columbus, OH, USA; Jonathan Finder, Children’s Hospital of Pittsburg, Pittsburg, PA, USA
- Emery AEH. The muscular dystrophies. 2002;359:687-695 10.1016/S0140-6736(02)07815-7
- Emery AEH. Population frequencies of inherited neuromuscular diseases—A world survey. 1991;1:19-29 10.1016/0960-8966(91)90039-U
- Mah JK, Korngut L, Dykeman J, Day L, Pringsheim T, Jette N. A systematic review and meta-analysis on the epidemiology of Duchenne and Becker muscular dystrophy. 2014;24:482-491 10.1016/j.nmd.2014.03.008
- Darras BT, Miller DT, Urion DK. Dystrophinopathies. ed. GeneReviews: University of Washington, Seattle, Seattle (WA), 1993.
- Bushby K, Finkel R, Birnkrant DJ, et al. Diagnosis and management of Duchenne muscular dystrophy, part 1: diagnosis, and pharmacological and psychosocial management. Lancet Neurology 2010;9:77-93 10.1016/s1474-4422(09)70271-6
- Cyrulnik SE, Fee RJ, Batchelder A, Kiefel J, Goldstein E, Hinton VJ. Cognitive and adaptive deficits in young children with Duchenne muscular dystrophy (DMD). 2008;14:853-861 10.1017/S135561770808106X
- Bushby K, Finkel R, Birnkrant DJ, et al. Diagnosis and management of Duchenne muscular dystrophy, part 2: implementation of multidisciplinary care. Lancet Neurology 2010;9:177-89 10.1016/s1474-4422(09)70272-8
- Eagle M, Bourke J, Bullock R, et al. Managing Duchenne muscular dystrophy – The additive effect of spinal surgery and home nocturnal ventilation in improving survival. 2007;17:470-475 10.1016/j.nmd.2007.03.002
- Parent Project Muscular Dystrophy. Parent Project Muscular Dystrophy Website. Available from: http://www.parentprojectmd.org.
- United Parent Projects Muscular Dystrophy. United Parent Projects Muscular Dystrophy Website. [Available from: http://www.uppmd.org]
- TREAT-NMD Alliance. TREAT-NMD Alliance Website ; Available from: http://www.treat-nmd.eu.
- MDA, PPMD, TREAT-NMD, UPPMD. The Diagnosis and Management of Duchenne Muscular Dystrophy: A Guide for Families. 2010; Available from: http://www.treat-nmd.eu/dmd-care-family.
- Cripe L, Kinnett K. Transforming Duchenne Care: meeting 25-26 June 2012, Ft. Lauterdale, Florida, USA. 2013; 8:690-5 10.1016/j.nmd.2013.05.002.
- Budych K, Helms TM, Schultz C. How do patients with rare diseases experience the medical encounter? Exploring role behavior and its impact on patient–physician interaction. 2012;105:154-164 10.1016/j.healthpol.2012.02.018
- Roger S, Woods K, Bladen C, et al. Adult care of Duchenne muscular dystropy in the UK. J Neuro. 2014; e-publication available at http://link.springer.com/article/10.1007%2Fs00415-014-7585-3
- Salzman B, Collins L, Hajjar ER. Chronic Disease Management: The Changing Landscape of Primary Care. 2012;39:xv-xxi 10.1016/j.pop.2012.04.002
- Edwards JH. The population genetics of Duchenne: natural and artificial selection in Duchenne muscular dystrophy. 1986;23:521-530 10.1136/jmg.23.6.521
- Poysky J, Kinnett K. Facilitating family adjustment to a diagnosis of Duchenne muscular dystrophy: April 24–25, 2008, Miami, Florida. 2009;19:733-738 10.1016/j.nmd.2009.07.011
- Romitti P, Puzhankara S, Mathews K, et al. Prevalence of Duchenne/Becker muscular dystrophy among males aged 5-24 years-four states, 2007. 2009;58:1119-1122
- Kole A, Faurisson F, Mavris M. The Voice of 12,000 Patients: Experiences and Expectations of Rare Disease Patients on Diagnosis and Care in Europe. 2009 Available from:: http://www.eurordis.org/IMG/pdf/voice_12000_patients/EURORDISCARE_FULLBOOKr.pdf.
- Hoogerwaard EM, van der Wouw PA, Wilde AAM, et al. Cardiac involvement in carriers of Duchenne and Becker muscular dystrophy. 1999;9:347-351 10.1016/S0960-8966(99)00018-8
- Van Westrum SMS, Hoogerwaard EM, Dekker L, et al. Cardiac abnormalities in a follow-up study on carriers of Duchenne and Becker muscular dystrophy. 2011;77:62-66 10.1212/WNL.0b013e318221ad14
- Martigne L, et al. Natural evolution of weight status in Duchenne muscular dystrophy: a tetrospective autid. Gr J Nutr.2011;10: 1486-1491.
- Finder JD, Birnkrant D, Carl J, et al. Respiratory care of the patient with Duchenne muscular dystrophy: ATS consensus statement. American journal of respiratory and critical care medicine 2004;170:456-65 10.1164/rccm.200307-885ST
- Gibson BE, Zitzelsberger H, McKeever P. ‘Futureless persons’: shifting life expectancies and the vicissitudes of progressive illness. 2009;31:554-568 10.1111/j.1467-9566.2008.01151.x
- Cripe LH, Tobias JD. Cardiac considerations in the operative management of the patient with Duchenne or Becker muscular dystrophy. 2013;23:777-784 10.1111/pan.12229
- Gurnaney H, Brown A, Litman RS. Malignant Hyperthermia and Muscular Dystrophies. 2009;109:1043-1048 10.1213/ane.0b013e3181aa5cf6
- Wang J, Stanley T. Duchenne muscular dystrophy and malignant hyperthermia - two case reports. Can Anaesth Soc J 1986;33:492-497 10.1007/BF03010977